Pan Cancer

Our comprehensive MayoComplete solid tumor panel analyzes 515 genes for mutations, rearrangements, amplifications, homozygous gene deletions, and/or transcript variants as well as evaluates for tumor mutation burden (TMB) and microsatellite instability (MSI) status to provide detailed insights on diagnosis, prognosis, and treatment response. Because obtaining sufficient tissue for multiple molecular and histological tests can be challenging, we have optimized specimen requirements by reducing the amount of FFPE tissue required and accept cytology as an alternative specimen type.

Key testing

• MCSTP | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor

Advantages

• Assists in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with solid tumors.
• Identifies sequence alterations in 515 genes, amplification of 96 genes, homozygous deletion of 133 genes, as well as detection of fusions involving 55 genes and complete inactivation of 31 tumor suppressor genes.
• Evaluates tumor mutation burden (TMB) status and microsatellite instability (MSI).
• Can assist in determining eligibility for clinical trials.
• Can be performed on both formalin-fixed, paraffin-embedded (FFPE) tissue and cytology specimens, including smears.